| Name | Title | Contact Details |
|---|
We empower the most underserved stakeholder in the healthcare system – the family caregiver. While training programs exist for home health aides or nurses to help manage care of the elderly, family members, who provide 80%+ of care to loved ones aging-in-place, have limited access to training. For example, actionable education like how to prevent falls in the house, safely transfer from a bed or chair, or manage difficult behaviour when a loved one has dementia. Recognizing that this content exists but isn`t available to families, Trualta adapted professional-level healthcare training for the family member audience. We deliver the training via an informal and interactive online learning environment, and tailor the learning to each caregiver`s situation. The program incentivizes engagement with a rewards system, and users can redeem rewards for helpful products and services. Our customers, healthcare payers and providers in Canada & the US, offer Trualta at point-of-care to better enable families to transition aging loved ones from hospital to home, and sustain independent living. Through clinical validation studies in the US and Canada, we are linking participation in Trualta`s program to improved outcomes and reduced costs. We are a proud resident company of the Biomedical Zone in downtown Toronto and the Invest Ottawa Accelerator program. If you are passionate about educating and enabling families to improve care for our aging population, drop us a note at info@trualta.com – we`d love to hear from you.
Mercy Health System is the largest Catholic healthcare system serving the Delaware Valley and is a member of Catholic Health East, a multi-institutional, Catholic health system co-sponsored by 13 religious congregations and Hope Ministries.
At Clinipace, a global, full-service contract research organization (CRO), our approach to clinical research is personal. We deliver a level of collaboration and flexibility not possible in a traditional CRO environment. Our personalized services and solutions, local regulatory expertise and therapeutic leadership are designed to face the most difficult industry challenges across all major therapeutic areas including oncology, gastroenterology, nephrology and urology. We strive to improve the way clinical research is performed and impact the future of health care using the most advanced technology and a CHALLENGE ACCEPTED approach. In April 2021, Clinipace & dMed merged creating a differentiated mid-size CRO with the largest Asia-Pacific presence. We are proud to have such a strong group of global investors focused on improving healthcare outcomes and giving sponsors a better CRO choice. dMed`s 2019 acquisition of Target Health commenced the process of building a Next Generation global CRO for biotech and pharmaceutical companies. Our investors have invested over $230M to build the next great global CRO. dMed`s acquisition of Target Health in 2019 began dMed`s evolution from a local to global CRO. Target Health LLC is owned by dMedClinical Co. Ltd., a privately held company that is majority owned, operated, managed, and controlled by a U.S. citizen and foreign entities located in the People`s Republic of China. Dr. Lingshi Tan, is the aforementioned U.S. citizen currently residing in Shanghai, China. Dr. Tan moved to Shanghai (from New York) to become Pfizer`s VP of Worldwide Development Operations, and Chairman and General Manager of Pfizer (China) Research & Development Co. Dr. Tan founded dMed in 2016 to satisfy the local demand for a high quality, responsive, flexible CRO.
A regenerative medicine company based on naturally-produced products from newborn fibroblasts grown in a proprietary bioreactor. Two product families - a proprietary liquid complex of embryonic-like proteins and growth factors` and a human Extracellular Matrix (ECM) material` ExCeltrix..